Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2
F. Amanat, S. Strohmeier, P. Meade, N. Dambrauskas, B. Mühlemann, D. J. Smith, V. Vigdorovich, D. N. Sather, L. Coughlan, F. Krammer
This study evaluates cross-neutralizing antibody responses and protective efficacy of vaccines based on SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 in mice against wild type SARS-CoV-2 challenge.
bioRxiv · Aug 5, 2021 · PreprintImmunology